ACTIVE

HARMONIE PHARMA

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

-62,2 k €

+73.0% YoY

Gross margin

81,5 k €

+236.9% YoY

Equity

234,9 k €

-20.9% YoY

What does HARMONIE PHARMA do?

HARMONIE PHARMA is a Private limited company incorporated in 1997. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Bruxelles.

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0461.800.766

Incorporation

30/10/1997

Legal form

Private limited company

Registered office

Rue de Laeken 129
1000 Bruxelles · BruxellesSee on map

Contributed capital

18 600,00 €

Latest accounts

31/12/2025

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Signals

Solid equityLow riskGood liquidityHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 18 financial years

	2025		2024		2023		2022		2021		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	81,5 k €	+237%	-59,5 k €	-168%	87,6 k €	-65.5%	253,6 k €	+200%	84,5 k €	-14.7%	99 k €	-13.3%	114,2 k €	-21.6%	145,7 k €	-11.0%	163,7 k €	-20.9%	207 k €	+17.4%	176,3 k €	+67.1%	105,5 k €	+10814%	-985 €	+11.9%	-1,1 k €	-10.8%	-1 k €	+9.1%	-1,1 k €	-38.3%	-802,5 €	-122%	-361 €
EBITDA	-61,5 k €	+51.8%	-127,5 k €	-246%	87,5 k €	-65.5%	253,5 k €	+202%	84,1 k €	-13.9%	97,7 k €	+10.2%	88,6 k €	+61.9%	54,7 k €	-44.8%	99,3 k €	-37.5%	158,8 k €	+7.7%	147,4 k €	+505%	24,4 k €	+2574%	-985 €	+11.9%	-1,1 k €	-10.8%	-1 k €	+9.1%	-1,1 k €	-38.3%	-802,5 €	-122%	-361 €
Operating result	-69,3 k €	+48.8%	-135,4 k €	-273%	78,1 k €	-68.2%	245,5 k €	+644%	33 k €	-27.2%	45,3 k €	+23.6%	36,7 k €	+396%	7,4 k €	-84.5%	47,6 k €	-55.3%	106,5 k €	+11.1%	95,8 k €	+92.8%	49,7 k €	+167%	-74,5 k €	-6565%	-1,1 k €	-10.8%	-1 k €	+9.1%	-1,1 k €	-22.3%	-907,9 €	-94.8%	-466,2 €
Net result	-62,2 k €	+73.0%	-230 k €	-271%	134,3 k €	-24.1%	177 k €	+780%	20,1 k €	-49.5%	39,8 k €	+350%	8,8 k €	+227%	-7 k €	-128%	25,2 k €	-63.1%	68,3 k €	-15.8%	81,2 k €	+112%	38,4 k €	+151%	-74,5 k €	-6565%	-1,1 k €	-10.8%	-1 k €	+9.1%	-1,1 k €	-21.9%	-910,4 €	-95.3%	-466,2 €
Balance sheet
Equity	234,9 k €	-20.9%	297,1 k €	-43.6%	527,1 k €	+34.2%	392,8 k €	+82.0%	215,8 k €	+10.9%	194,6 k €	-0.1%	194,7 k €	+12.2%	173,5 k €	-3.9%	180,5 k €	+16.2%	155,3 k €	+78.6%	87 k €	+1399%	5,8 k €	+118%	-32,6 k €	-178%	41,9 k €	-2.6%	43,1 k €	-2.3%	44,1 k €	-2.5%	45,2 k €	-2.0%	46,1 k €
Total assets	456,1 k €	+27.4%	358,2 k €	-46.0%	663,7 k €	+1.7%	652,6 k €	+15.5%	565,1 k €	-9.3%	622,8 k €	+0.3%	620,7 k €	-8.9%	681,3 k €	-6.6%	729,7 k €	+8.1%	675 k €	+8.4%	622,8 k €	-1.2%	630,1 k €	+76560%	822 €	-98.9%	74,3 k €	+0.0%	74,3 k €	+0.6%	73,8 k €	+0.2%	73,7 k €	-0.1%	73,8 k €
Cash	141,9 k €	+142%	58,7 k €	+6.5%	55,1 k €	+39.4%	39,5 k €	-33.1%	59,1 k €	+132%	25,4 k €	-63.1%	68,8 k €	-52.7%	145,6 k €	+141%	60,6 k €	+228%	18,5 k €	-18.2%	22,6 k €	+18.7%	19 k €		0 €	-100%	0 €		–		0 €	0.0%	0 €	0.0%	0 €
Debts	221,3 k €	+262%	61,1 k €	-55.3%	136,6 k €	-47.4%	259,9 k €	-25.6%	349,3 k €	-18.4%	428,2 k €	+0.5%	426 k €	-14.1%	496 k €	-9.7%	549,2 k €	+5.7%	519,5 k €	-3.1%	535,9 k €	-14.2%	624,3 k €	+1770%	33,4 k €	+3.2%	32,3 k €	+3.7%	31,2 k €	+4.8%	29,8 k €	+4.5%	28,5 k €	+2.9%	27,7 k €
Other
Workforce	–		–		–		–		0,0 ETP		–		2,4 ETP	-4.0%	2,5 ETP	+25.0%	2,0 ETP	+25.0%	1,6 ETP	+23.1%	1,3 ETP	+333%	0,3 ETP		–		–		–		–		–		–

Estimate

Indicative valuation

As an indication, this company is worth

between 100 k€ and 250 k€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 14 ended

Active mandates

GROUPE TETE PHARMACEUTICAL

Director · since 08 mai 2026 · 0542.600.182

Represented by Tete Kwassigan Tsonyuido

Active

Ended mandates

Novesta

Manager · since 01 juin 2017 · 0568.541.447

Represented by Him Omar

Ended

Novesta

Director · since 01 juin 2017 · 0568.541.447

Represented by Him Omar

Ended

Shilan OMAR

Mandate · since 01 octobre 2012

Ended

GESTIOPHARM SPRL

Manager · 0476.704.223

Ended

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Micro model	Micro model	Micro model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	31/08/2026	16/12/2025	27/06/2024	31/07/2023	25/08/2022	17/08/2021
General meeting	24/08/2026	22/10/2025	27/06/2024	30/06/2023	30/06/2022	30/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

20 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Micro model	31/12/2025	24/08/2026	31/08/2026	Dutch	PDF
Micro model	31/12/2024	22/10/2025	16/12/2025	Dutch	PDF
Micro model	31/12/2023	27/06/2024	27/06/2024	Dutch	PDF
Abridged model	31/12/2022	30/06/2023	31/07/2023	French	PDF
Abridged model	31/12/2021	30/06/2022	25/08/2022	Dutch	PDF
Abridged model	31/12/2020	30/06/2021	17/08/2021	Dutch	PDF
Abridged model	31/12/2019	30/06/2020	04/08/2020	Dutch	PDF
Abridged model	31/12/2018	28/06/2019	24/07/2019	Dutch	PDF
Abridged model	31/12/2017	12/06/2018	29/08/2018	French	PDF
Abridged model	31/12/2016	13/06/2017	22/08/2017	French	PDF
Abridged model	31/12/2015	14/06/2016	11/08/2016	French	PDF
Abridged model	31/12/2014	09/06/2015	17/09/2015	French	PDF
Abridged model	31/12/2013	10/06/2014	28/08/2014	French	PDF
Abridged model	31/12/2012	11/06/2013	11/07/2013	French	PDF
Abridged model	31/12/2011	09/03/2012	09/03/2012	French	PDF
Abridged model	31/12/2010	07/06/2011	17/08/2011	French	PDF
Abridged model	31/12/2009	08/06/2010	26/08/2010	French	PDF
Abridged model	31/12/2008	02/06/2009	04/08/2009	French	PDF
Abridged model	31/12/2007	03/06/2008	18/08/2008	French	PDF
Abridged model	31/12/2006	05/06/2007	27/08/2007	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 k€ and 250 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 14 ended

Active mandates

GROUPE TETE PHARMACEUTICAL

Director · since 08 mai 2026 · 0542.600.182

Represented by Tete Kwassigan Tsonyuido

Active

Ended mandates

Novesta

Manager · since 01 juin 2017 · 0568.541.447

Represented by Him Omar

Ended

Novesta

Director · since 01 juin 2017 · 0568.541.447

Represented by Him Omar

Ended

Shilan OMAR

Mandate · since 01 octobre 2012

Ended

GESTIOPHARM SPRL

Manager · 0476.704.223

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates20/05/2026
DENOMINATION
PDF
Mandates17/04/2026
ONTSLAGEN - BENOEMINGEN
PDF
Mandates12/07/2024
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - BENAMING - ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
PDF
Mandates16/06/2017
ONTSLAGEN - BENOEMINGEN
PDF
Mandates21/09/2016
BENAMING - ONTSLAGEN - BENOEMINGEN
PDF
Mandates18/07/2016
ONTSLAGEN - BENOEMINGEN
PDF
Mandates31/05/2016
ONTSLAGEN - BENOEMINGEN
PDF
Mandates12/10/2012
DEMISSIONS, NOMINATIONS
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025-62,2 k €↑
2024
Annual accounts 2024-230 k €↓
2024
Name changePHARMA YSER
2023
Annual accounts 2023134,3 k €↓
2022
Annual accounts 2022177 k €↑
2021
Annual accounts 202120,1 k €↓
2021
Name changeBELLIPHARMA YSER
2018
Annual accounts 201839,8 k €↑
2017
Annual accounts 20178,8 k €↑
2016
Annual accounts 2016-7 k €↓
2015
Annual accounts 201525,2 k €↓
2014
Annual accounts 201468,3 k €↓
2013
Annual accounts 201381,2 k €↑
2012
Annual accounts 201238,4 k €↑
2011
Annual accounts 2011-74,5 k €↓
2010
Annual accounts 2010-1,1 k €↓
2009
Annual accounts 2009-1 k €↑
2008
Annual accounts 2008-1,1 k €↓
2007
Annual accounts 2007-910,4 €↓
2006
Annual accounts 2006-466,2 €
30/10/1997
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

HARMONIE PHARMA

Overview

What does HARMONIE PHARMA do?

Trend over 18 financial years

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline